The rest 120 drugs are previously or currently being investigated in clinical trials with no significant reported side effects, targeting specific signaling pathways that are crucial for CA formation, including Wnt/β-catenin, TGF-β/SMAD, JAK/STAT, MAPK, and DNA mismatch repair. Here, TGFB1 is linked to cancer.